Chemical Structure For Cilostazol (Image 1)
Cilostazol Tablet
Product Images NDC 63629-8796
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Cilostazol (NDC 63629-8796). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure1 (Image 2)
This is a chart displaying the plasma concentration in ng/mL of three substances: cilostazol, 3,4-dehydrocilostazol, and 4'-trans-hydroxycilostazol over time in hours. The exact values are not provided, only markers on the graph.*
Figure 2 (Image 3)
This is a chart that shows the percent mean improvement in maximal walking distance for different treatments over different durations of time. The treatments are Placebo, Cilostazol 50 mg bid, and Cilostazol 100 mg bid. The durations are 12 weeks, 16 weeks, and 24 weeks. The chart shows that both doses of Cilostazol had a greater mean improvement in walking distance than Placebo, and that increased duration of treatment also led to greater improvement.*
Label (Lbl636298796)
This is a description of Cilostazol Tablets USP, which contains 50 mg cilostazol per tablet. The medication is to be stored at 20° to 25°C (68° to 77°F) and kept out of reach of children in a child-resistant container, as per USP regulations. The usual dosage is 1 tablet twice daily. The NDC number is 63629-8796-1 and the package contains 60 tablets.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
